Related by context. Frequent words. (Click for all words.) 54 TranSwitch indebtedness 50 commercial bioproduction 50 Traficet EN 49 development diagnostics combinatorial 49 Nothing vulgar obscene 49 obj obj = 47 Safe Harbors created 46 related = document.getElementById 46 geology continuity 46 * Potentially libelous 46 TranSwitch filings 45 pharmacokinetics PK 44 dose cohorts 44 inflammation autoimmune diseases 43 document.getElementById root root 43 risks anduncertainties 43 within themeaning 42 Prelude SkinPrep Systems 42 regarding Heska 42 suchforward looking 42 RXi Pharmaceutical Corporation 41 xxii 41 pharmacokinetic parameters 41 intents beliefs 41 HIV uninfected 41 efficacy 41 pharmacodynamic 41 PTOI 40 Charge VOP 40 Nortel restatements 40 Dedicated FN channel 40 Carrie Rickey 40 theSecurities 40 leading broadline retailer 40 mortality morbidity 39 eprodisate KIACTA TM 39 incorporated therein 39 relating 39 HBeAg positive 39 indentures governing certain 39 Estimates typically exclude 39 incur unanticipated 39 Intangibles amortization 39 metastatic RCC 39 ultimate recoverability 39 HIV human immunodeficiency 39 ascending doses 38 xxvii 38 Disputes arising 38 NLX P# 38 pharmacokinetics 38 tables summarize 38 APTIVUS r 38 inattention hyperactivity 38 www.audiusanews.com 38 issuable upon exercise 37 Non GAAP adjustments 37 Octane Additives 37 anthropology sociology 37 PREZISTA r 37 Partially offset 37 feedback@financialwire.net 37 xxvi 37 vii 37 principally attributable 37 subjects 37 evaluable 36 analgesic efficacy 36 diminishing quantities 36 xvi 36 Secondary endpoints 36 osteoporosis arthritis 36 basedon 36 - Operating [004] 36 EVIZON 36 Alzheimer disease Parkinson disease 36 inventory obsolescence 36 viii 35 concomitant medications 35 laboratory abnormalities 35 xxi 35 governmental approvals 35 news@wbrz.com 35 xix 35 Non Controlling Interest 35 debt extinguishments 35 xxv 35 related thereto 35 efficacy endpoints 35 TEAEs 35 acquisitions divestitures mergers 35 normotensive 35 anatomy physiology 34 illiquid restricted 34 double blinded placebo 34 consequential amendments 34 secondary efficacy endpoints 34 apremilast 34 incentive accruals 34 postretirement benefit plans 34 Statements Certain